August 12nd, 2025
Inhibiting a specific gene, MET, in combination with standard chemotherapy and immunotherapy, enhances treatment efficacy and limits tumor growth in small cell lung cancer (SCLC). The study, led by the Hospital del Mar Research Institute, analyzed the effect of MET inhibition in mouse models and studied gene expression in patient tumor samples. The results are published in Cell Reports Medicine. Researchers aim to pursue this line of research with a clinical trial involving patients.
August 5th, 2025
70% of Chronic Obstructive Pulmonary Disease (COPD) cases go undiagnosed. Now, a study led by Hospital del Mar and the Hospital del Mar Research Institute has validated ten metabolites that are altered in patients with this disease. These metabolites can be identified through a simple blood test, which opens the door to their use in future population-based screening for suspected COPD. The study used artificial intelligence tools to determine which of these molecules yielded the most accurate results.
Read more sobre "Progress Toward a Population Screening Test for COPD"
July 31st, 2025
This is indicated by the results of the PENSA study, a clinical trial conducted jointly by the Research Institute of Hospital del Mar and the Barcelonaβeta Brain Research Center, the research center of the Pasqual Maragall Foundation. The study concludes that combining a healthy lifestyle program with epigallocatechin gallate (EGCG), a natural compound found in green tea, could offer sustained cognitive benefits in people at high risk of developing Alzheimer's disease. Over the course of one year, around one hundred cognitively healthy volunteers, but in stages potentially prior to the onset of dementia, were monitored. They were divided into three groups. One group received only healthy lifestyle advice. The other two groups underwent a lifestyle improvement intervention program combined with either EGCG or placebo. Almost half of the participants who received the lifestyle program combined with EGCG improved their cognition, compared to 30% of those in the lifestyle program combined with the placebo group. These cognitive benefits in the EGCG group were maintained after the treatment ended. The study also highlights the effect of following a healthy lifestyle. Compared to participants who only received healthy lifestyle advice, those who completed the full intervention program improved their cognition up to 4.5 times more if they took EGCG, and up to 3 times more if they took placebo. Furthermore, both intervention groups reduced the risk of developing dementia by approximately 25%.
8 de septiembre de 2025
5 de octubre de 2025
9 de octubre de 2025
Parc Salut Mar
Passeig Marítim 25-29 Barcelona 08003
See location on Google maps
Phone: 93 248 30 00 · Fax: 93 248 32 54
Information request
© 2006 - 2025 Hospital del Mar · Legal notice and Privacy Police | Cookie Policy | Accessibility
